Drug intelligence / Profile preview

LT-4001

Development stage: Unknown
Lead developer: LTT Bio-Pharma
Modality: Small Molecules

Overview

LT-4001 is a drug repositioning candidate being developed by LTT Bio-Pharma for the treatment of Chronic Obstructive Pulmonary Disease (COPD). LTT Bio-Pharma, a Japanese pharmaceutical company, utilizes a drug repositioning (DR) approach to identify new therapeutic applications for existing drugs with established safety profiles. LT-4001 is currently in Phase 2 clinical development for COPD. While the specific active ingredient and molecular target have not been publicly disclosed, the program aims to provide a new treatment option for respiratory diseases by leveraging the company's expertise in drug delivery systems and repositioning strategies.

Other names: Drug re-positioning (DR)

Beyond the preview

Go deeper on LT-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-4001.

Explore the full profile